Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>

Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2023-11-29 Purchase | 2023-12-01 5:15 pm | Y-mAbs Therapeutics Inc. | YMAB | WG Biotech ApS Director | 51,837 | $5.9702 | $309,477 | 4,425,229 (Direct) | View |
2023-11-29 Purchase | 2023-12-01 5:14 pm | Y-mAbs Therapeutics Inc. | YMAB | Wedell-Wedellsborg Johan Director | 51,837 | $5.9702 | $309,477 | 4,425,229 (Indirect) | View |
2023-11-27 Purchase | 2023-11-29 5:15 pm | Y-mAbs Therapeutics Inc. | YMAB | Wedell-Wedellsborg Johan Director | 93,187 | $5.5941 | $521,294 | 4,373,392 (Indirect) | View |
2023-11-27 Purchase | 2023-11-29 5:14 pm | Y-mAbs Therapeutics Inc. | YMAB | WG Biotech ApS Director | 93,187 | $5.5941 | $521,294 | 4,373,392 (Direct) | View |
2023-11-20 Sale | 2023-11-22 5:00 pm | Y-mAbs Therapeutics Inc. | YMAB | Gad Thomas Chief Business Officer | 150,000 | $5.3026 | $795,383 | 565,532 (Indirect Direct) | View |
2023-05-15 Purchase | 2023-05-17 5:07 pm | Y-mAbs Therapeutics Inc. | YMAB | Wedell-Wedellsborg Johan Director | 101,740 | $9.6462 | $981,404 | 4,280,205 (Indirect) | View |
2023-05-15 Purchase | 2023-05-17 5:05 pm | Y-mAbs Therapeutics Inc. | YMAB | WG Biotech ApS See remarks | 101,740 | $9.6462 | $981,404 | 4,280,205 (Direct) | View |
2022-11-15 Purchase | 2022-11-16 7:01 pm | Y-mAbs Therapeutics Inc. | YMAB | Rajah Vignesh SVP & CMO | 1,195 | $4.924 | $5,884 | 4,266 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2023-11-06 Option Award | 2023-11-08 5:19 pm | N/A 2033-11-06 | Y-mAbs Therapeutics Inc. | YMAB | Gad Thomas Chief Business Officer | 75,000 | $0 | 75,000 (Direct) | View |
2023-11-06 Option Award | 2023-11-08 5:16 pm | N/A 2033-11-06 | Y-mAbs Therapeutics Inc. | YMAB | Rossi Michael J President and CEO | 615,240 | $0 | 615,240 (Direct) | View |
2023-06-08 Option Award | 2023-06-09 6:05 pm | N/A 2033-06-08 | Y-mAbs Therapeutics Inc. | YMAB | Hamill Laura Director | 16,280 | $0 | 16,280 (Direct) | View |
2023-06-08 Option Award | 2023-06-09 6:04 pm | N/A 2033-06-08 | Y-mAbs Therapeutics Inc. | YMAB | Wedell-Wedellsborg Johan Director | 16,280 | $0 | 4,296,485 (Direct) | View |
2023-06-08 Option Award | 2023-06-09 6:02 pm | N/A 2033-06-08 | Y-mAbs Therapeutics Inc. | YMAB | Ber Gerard Director | 16,280 | $0 | 16,280 (Direct) | View |
2023-06-08 Option Award | 2023-06-09 6:01 pm | N/A 2033-06-08 | Y-mAbs Therapeutics Inc. | YMAB | GILL DAVID N Director | 16,280 | $0 | 16,280 (Direct) | View |
2023-06-08 Option Award | 2023-06-09 6:00 pm | N/A 2033-06-08 | Y-mAbs Therapeutics Inc. | YMAB | HEALY JAMES Director | 16,280 | $0 | 2,236,336 (Direct) | View |
2023-06-08 Option Award | 2023-06-09 6:00 pm | N/A 2033-06-08 | Y-mAbs Therapeutics Inc. | YMAB | TYAGI ASHU Director | 16,280 | $0 | 16,280 (Direct) | View |
2023-01-26 Option Award | 2023-01-30 4:35 pm | N/A 2033-01-26 | Y-mAbs Therapeutics Inc. | YMAB | Lisby Steen SVP & CHIEF SCIENTIFIC OFFICER | 32,000 | $0 | 32,000 (Direct) | View |
2023-01-26 Option Award | 2023-01-30 4:34 pm | N/A 2033-01-26 | Y-mAbs Therapeutics Inc. | YMAB | Lund-Hansen Torben SVP & CHIEF TECHNICAL OFFICER | 32,000 | $0 | 32,000 (Direct) | View |
2023-01-26 Option Award | 2023-01-30 4:33 pm | N/A 2033-01-26 | Y-mAbs Therapeutics Inc. | YMAB | Rajah Vignesh SVP & CHIEF MEDICAL OFFICER | 32,000 | $0 | 32,000 (Direct) | View |
2023-01-26 Option Award | 2023-01-30 4:32 pm | N/A 2033-01-26 | Y-mAbs Therapeutics Inc. | YMAB | Smith Susan Laura SVP & CHIEF COMMERCIAL OFFICER | 32,000 | $0 | 32,000 (Direct) | View |
2023-01-26 Option Award | 2023-01-30 4:31 pm | N/A 2033-01-26 | Y-mAbs Therapeutics Inc. | YMAB | Wilms Joris SVP & CHIEF OPERATING OFFICER | 32,000 | $0 | 32,000 (Direct) | View |
2023-01-17 Option Award | 2023-01-19 4:45 pm | N/A 2033-01-17 | Y-mAbs Therapeutics Inc. | YMAB | Rajah Vignesh SVP & CHIEF MEDICAL OFFICER | 53,500 | $0 | 57,766 (Direct) | View |
2023-01-17 Option Award | 2023-01-19 4:44 pm | N/A 2033-01-17 | Y-mAbs Therapeutics Inc. | YMAB | Lund-Hansen Torben SVP & CHIEF TECHNICAL OFFICER | 53,500 | $0 | 99,162 (Direct) | View |
2023-01-17 Option Award | 2023-01-19 4:42 pm | N/A 2033-01-17 | Y-mAbs Therapeutics Inc. | YMAB | Gad Thomas See remarks | 283,700 | $0 | 958,732 (Direct) | View |
2023-01-17 Option Award | 2023-01-19 4:40 pm | N/A 2033-01-17 | Y-mAbs Therapeutics Inc. | YMAB | Smith Susan Laura SVP & CHIEF COMMERCIAL OFFICER | 53,500 | $0 | 53,500 (Direct) | View |
2023-01-17 Option Award | 2023-01-19 4:39 pm | N/A 2033-01-17 | Y-mAbs Therapeutics Inc. | YMAB | Lisby Steen SVP & CHIEF SCIENTIFIC OFFICER | 53,500 | $0 | 53,500 (Direct) | View |
2023-01-17 Option Award | 2023-01-19 4:36 pm | N/A 2033-01-17 | Y-mAbs Therapeutics Inc. | YMAB | Wilms Joris SVP & CHIEF OPERATING OFFICER | 53,500 | $0 | 53,500 (Direct) | View |
2023-01-17 Option Award | 2023-01-19 4:34 pm | N/A 2033-01-17 | Y-mAbs Therapeutics Inc. | YMAB | Kruse Bo EVP, CFO, Secry & Treas. | 81,800 | $0 | 262,877 (Direct) | View |
2022-07-15 Option Award | 2022-07-19 1:24 pm | N/A 2032-07-14 | Y-mAbs Therapeutics Inc. | YMAB | Hamill Laura Director | 16,000 | $0 | 16,000 (Direct) | View |
2022-07-15 Option Award | 2022-07-19 1:23 pm | N/A 2032-07-14 | Y-mAbs Therapeutics Inc. | YMAB | Wedell-Wedellsborg Johan Director | 16,000 | $0 | 16,000 (Direct) | View |
2022-07-15 Option Award | 2022-07-19 1:22 pm | N/A 2032-07-14 | Y-mAbs Therapeutics Inc. | YMAB | HEALY JAMES Director | 16,000 | $0 | 16,000 (Direct) | View |
2022-07-15 Option Award | 2022-07-19 1:21 pm | N/A 2032-07-14 | Y-mAbs Therapeutics Inc. | YMAB | Ber Gerard Director | 16,000 | $0 | 16,000 (Direct) | View |
2022-07-15 Option Award | 2022-07-19 1:20 pm | N/A 2032-07-14 | Y-mAbs Therapeutics Inc. | YMAB | GILL DAVID N Director | 16,000 | $0 | 16,000 (Direct) | View |
2022-07-15 Option Award | 2022-07-19 1:18 pm | N/A 2032-07-14 | Y-mAbs Therapeutics Inc. | YMAB | TYAGI ASHU Director | 16,000 | $0 | 16,000 (Direct) | View |
2022-05-18 Option Award | 2022-05-19 4:16 pm | N/A 2032-05-18 | Y-mAbs Therapeutics Inc. | YMAB | Gad Thomas See remarks | 60,000 | $0 | 60,000 (Direct) | View |
2022-04-26 Option Award | 2022-04-28 6:22 pm | N/A 2032-04-26 | Y-mAbs Therapeutics Inc. | YMAB | Rajah Vignesh SVP & CMO | 20,000 | $0 | 20,000 (Direct) | View |
2022-04-26 Option Award | 2022-04-28 6:21 pm | N/A 2032-04-26 | Y-mAbs Therapeutics Inc. | YMAB | Lund-Hansen Torben SVP & CTO | 20,000 | $0 | 20,000 (Direct) | View |
2022-04-26 Option Award | 2022-04-28 6:20 pm | N/A 2032-04-26 | Y-mAbs Therapeutics Inc. | YMAB | Smith Susan Laura SVP & CCO | 20,000 | $0 | 20,000 (Direct) | View |
2022-04-26 Option Award | 2022-04-28 6:19 pm | N/A 2032-04-26 | Y-mAbs Therapeutics Inc. | YMAB | Lisby Steen SVP & CSO | 20,000 | $0 | 20,000 (Direct) | View |